The Test That Came Too Late: Why Hepatitis B Must Never Be Treated as the “Lesser” Infection

By The Unheard Voice

The Test That Came Too Late: Why Hepatitis B Must Never Be Treated as the “Lesser” Infection

He was a young man with haemophilia.

From the age of approximately 15, he received Factor VIII and later a platelet transfusion as part of his NHS care. Those treatments were supposed to help him live with his bleeding disorder.

Instead, his medical records would eventually list three devastating infections: HIV, hepatitis B and hepatitis C.

But buried among those records is one sentence that should stop us all:

“Looking back through his notes, it would appear that he has never been tested previously.”

That letter was dated January 1992. It recorded that positive hepatitis B serology had been discovered during routine testing in November 1990.

By then, he was 29 years old.

This was not a patient whose risk was unknown. He was a haemophiliac who had received blood products. He had already been diagnosed with HIV. His notes recorded abnormal liver results and other clinical signs.

Yet the surviving records suggest his hepatitis B infection was discovered not through a systematic effort to trace what had happened to him, but through routine testing years later.

We cannot use these documents to establish exactly when he contracted hepatitis B. We cannot say with certainty that earlier diagnosis would have prevented his death. He was also living with HIV and hepatitis C, and his liver disease may have had more than one contributing cause.

But we can ask the question the records leave behind:

Why did a patient with such an obvious history of exposure appear never to have been tested for hepatitis B until November 1990?

The warning was already there

A consultant’s letter from January 1991 recorded positive hepatitis B surface antigen and hepatitis B e antigen results. The doctor’s interpretation was stark: the findings indicated a “high level of carriage” and a “high infective risk.”

His liver-function results were also abnormal.

In September 1992, another medical letter described him as a hepatitis B carrier with HBe antigenaemia—again explaining that this meant a high risk of infectivity. That same letter recorded signs of chronic liver disease, both clinically and biochemically.

The sequence documented in these notes is deeply troubling:

* November 1990: hepatitis B was discovered during routine testing. * January 1991: doctors recorded high-level carriage, high infectivity and abnormal liver-function tests. * January 1992: a consultant wrote that the records suggested he had never previously been tested. * September 1992: chronic liver disease was being recorded clinically and biochemically. * October 1997: doctors again noted signs of chronic liver disease. * July 1998: the records described hepatitis B e antigen positivity and the stigmata of chronic liver disease. * April 1999: he was jaundiced, with an enlarged liver. An ultrasound was said to strongly suggest portal hypertension with underlying cirrhosis. * January 2000: his hospital records listed cirrhosis alongside HIV, hepatitis B, hepatitis C, marrow failure, a probable variceal bleed and hepatic encephalopathy. A decision was made that cardiopulmonary resuscitation would be inappropriate.

He died aged 38.

These are not the records of a harmless or insignificant infection.

They are the records of a young man whose hepatitis B status was detected late, whose liver disease became progressively more serious and whose final hospital notes documented advanced, life-threatening complications.

Hepatitis B can be silent

Hepatitis B is particularly dangerous because many people experience no symptoms—or only mild symptoms. Someone can look and feel relatively well while chronic infection is damaging the liver.

The NHS warns that untreated chronic hepatitis B can cause cirrhosis and increase the risk of liver cancer. It also says people who believe they may have hepatitis B, or are at increased risk, should speak to their GP.

The World Health Organization says laboratory confirmation is essential because hepatitis B cannot reliably be distinguished from other forms of viral hepatitis on symptoms alone. Blood tests can establish infection, help distinguish acute from chronic disease and support the monitoring of liver damage.

That is precisely why testing matters.

Waiting for jaundice, swelling, pain or obvious signs of liver failure is not a safe strategy. By the time visible symptoms appear, significant damage may already have occurred.

Testing is not merely about placing a diagnosis in somebody’s file. It can open the door to:

* specialist liver care; * regular monitoring of liver function and viral activity; * assessment for antiviral treatment; * surveillance for cirrhosis and liver cancer; * vaccination and testing for household or sexual contacts; * advice to reduce transmission; and * evidence that may later become vital for families seeking truth, accountability or compensation.

Current UK guidance says close household and sexual contacts of someone living with hepatitis B should be offered testing and vaccination. It also says timely monitoring and treatment can reduce the risk of cirrhosis and liver cancer after chronic infection is diagnosed.

“Carrier” did not mean unharmed

Older medical records frequently describe people as hepatitis B “carriers.” That language can create a dangerously reassuring impression—as though the virus were simply present without causing injury.

But this man’s own records show why that assumption is wrong.

One 1991 letter said his hepatitis B diagnosis would not affect his lifestyle because he was already taking precautions due to HIV. Yet the same letter recorded abnormal liver-function results and interpreted his blood markers as demonstrating high carriage and high infectivity.

By 1992, signs of chronic liver disease were recorded.

By 1999, he had jaundice and evidence of portal hypertension and cirrhosis.

Calling someone a “carrier” did not mean that person was safe. It did not mean the infection required no follow-up. It did not mean their liver would remain unharmed.

Most importantly, it should never mean their suffering is assigned less value.

The records contain a missed opportunity

Perhaps the most revealing part of the January 1992 letter is what happened after the clinician recognised the absence of earlier testing.

The consultant wrote that arrangements had now been made to store serum from haemophiliac patients at every outpatient attendance.

That change matters. It suggests the discovery prompted an alteration in practice—an acknowledgment that regular samples needed to be preserved.

But for the patient at the centre of these records, the system had already lost years.

Stored samples might have helped identify when infection occurred. Earlier testing could have established his status sooner. More complete records might have given him and his family clearer answers.

We cannot rewrite his medical history, and we should not claim an outcome the surviving evidence cannot prove. But the absence of testing deprived him of knowledge, deprived clinicians of an earlier baseline and left his family with questions that should never have survived him.

Hepatitis B must not remain in the shadows

Within the infected blood scandal, public attention has understandably focused heavily on HIV and hepatitis C. Their devastating consequences demand recognition.

But recognising those infections must not mean diminishing hepatitis B.

Hepatitis B can become chronic. It can remain silent. It can cause progressive liver damage, cirrhosis, liver failure and liver cancer. It can also expose partners and family members to risk when infection remains unidentified.

Globally, the World Health Organization estimated that hepatitis B caused approximately 1.1 million deaths in 2024, mainly through cirrhosis and primary liver cancer.

Behind those figures are people like the anonymous man in these records: a son, a brother and an uncle whose life ended at only 38.

His hepatitis B was not a footnote.

It was repeatedly recorded alongside chronic liver disease, high infectivity, portal hypertension and cirrhosis. It formed part of the devastating combination of infections documented in his final hospital records.

A call for testing—and for answers

Anyone who received blood, a blood transfusion or blood products in circumstances that may have exposed them to infection—particularly historically—should be able to discuss their individual risk and appropriate testing with a healthcare professional.

People should also seek advice if a parent, partner or household member has or had hepatitis B, or if they believe they may otherwise have been exposed. Testing involves blood tests, but interpreting hepatitis B markers can be complex and should be done by a qualified clinician.

This is not about causing panic. It is about preventing silence from doing further damage.

Health authorities must also ensure that people known to have been placed at risk are not expected to identify themselves by chance decades later. Risk should trigger proactive information, appropriate testing, vaccination where indicated, specialist referral and long-term monitoring.

The infected blood compensation system must recognise the true range of harm caused by hepatitis B, including chronic infection, serious liver disease, the psychological burden, transmission risks and the difficulties faced by families when historic tests or records are missing.

A virus does not become insignificant because another infection was also present.

A life does not become less valuable because several illnesses contributed to its loss.

And a failure to test should never be allowed to erase the evidence of what happened.

This family shared these records for one reason: so that somebody else might be tested before it is too late.

Hepatitis B must be tested for. It must be monitored. It must be properly recognised. And it must never again be treated as the lesser infection.

The family and patient have been anonymised. This article reflects the information contained in surviving medical records and does not attempt to determine a single medical cause of the patient’s liver disease or death.

— The Unheard Voice